Cardiol Therapeutics Inc. (CRDL)
- Previous Close
2.3600 - Open
2.3500 - Bid 2.1400 x 300
- Ask 2.1900 x 200
- Day's Range
2.1300 - 2.3980 - 52 Week Range
0.5900 - 2.4100 - Volume
345,211 - Avg. Volume
345,709 - Market Cap (intraday)
149.726M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.49
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
www.cardiolrx.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CRDL
Performance Overview: CRDL
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDL
Valuation Measures
Market Cap
148.48M
Enterprise Value
127.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.35%
Return on Equity (ttm)
-92.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.22M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
28.57M
Total Debt/Equity (mrq)
0.83%
Levered Free Cash Flow (ttm)
-10.19M
Research Analysis: CRDL
Company Insights: CRDL
CRDL does not have Company Insights